BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 28906385)

  • 1. Percutaneous intratumoral injection of gemcitabine plus cisplatin mixed with fibrin glue for advanced pancreatic carcinoma: Case Report.
    Yang B; He JP; Yuan ML; Li W; Jiao H; You X; Liu XR; Zhao J; Li CL; Fu XB; Liao ZY; Yi C
    Medicine (Baltimore); 2017 Sep; 96(37):e8018. PubMed ID: 28906385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoral Mistletoe (Viscum album L) Therapy in Patients With Unresectable Pancreas Carcinoma: A Retrospective Analysis.
    Schad F; Atxner J; Buchwald D; Happe A; Popp S; Kröz M; Matthes H
    Integr Cancer Ther; 2014 Jul; 13(4):332-40. PubMed ID: 24363283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategy for prevention of local recurrence of pancreatic cancer after pancreatectomy: antitumor effect of gemcitabine mixed with fibrin glue in an orthotopic nude mouse model.
    Ogura Y; Mizumoto K; Tanaka M; Ohuchida K; Murakami M; Yamada D; Ishikawa N; Nagai E
    Surgery; 2006 Jul; 140(1):66-71. PubMed ID: 16857444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head.
    Heinrich S; Pestalozzi BC; Schäfer M; Weber A; Bauerfeind P; Knuth A; Clavien PA
    J Clin Oncol; 2008 May; 26(15):2526-31. PubMed ID: 18487569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial.
    Reni M; Zanon S; Peretti U; Chiaravalli M; Barone D; Pircher C; Balzano G; Macchini M; Romi S; Gritti E; Mazza E; Nicoletti R; Doglioni C; Falconi M; Gianni L
    Lancet Gastroenterol Hepatol; 2018 Oct; 3(10):691-697. PubMed ID: 30220407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma.
    Reni M; Cereda S; Bonetto E; Viganò MG; Passoni P; Zerbi A; Balzano G; Nicoletti R; Staudacher C; Di Carlo V
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):361-7. PubMed ID: 16807732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942.
    Haddock MG; Swaminathan R; Foster NR; Hauge MD; Martenson JA; Camoriano JK; Stella PJ; Tenglin RC; Schaefer PL; Moore DF; Alberts SR
    J Clin Oncol; 2007 Jun; 25(18):2567-72. PubMed ID: 17577035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer].
    Gong JF; Zhang XD; Li J; Di LJ; Jin ML; Shen L
    Ai Zheng; 2007 Aug; 26(8):890-4. PubMed ID: 17697554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced Pancreatic Adenocarcinoma: Complete Histological Response After Palliative Therapy with Gemcitabine and Cisplatin.
    Alexander A; Rehders A; Riediger R; Schmitt M; Anlauf M; Knoefel WT
    J Gastrointest Cancer; 2012 Sep; 43 Suppl 1():S42-5. PubMed ID: 22528322
    [No Abstract]   [Full Text] [Related]  

  • 10. Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine.
    Kornek GV; Pötter R; Selzer E; Schratter A; Ulrich-Pur H; Rogy M; Kraus G; Scheithauer W
    Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):665-71. PubMed ID: 11172947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer.
    El-Rayes BF; Zalupski MM; Shields AF; Vaishampayan U; Heilbrun LK; Jain V; Adsay V; Day J; Philip PA
    J Clin Oncol; 2003 Aug; 21(15):2920-5. PubMed ID: 12885810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer--a multi-centre randomised phase II study.
    Wilkowski R; Boeck S; Ostermaier S; Sauer R; Herbst M; Fietkau R; Flentje M; Miethe S; Boettcher HD; Scholten T; Bruns CJ; Rau HG; Hinke A; Heinemann V
    Br J Cancer; 2009 Dec; 101(11):1853-9. PubMed ID: 19904268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma.
    Hecht JR; Bedford R; Abbruzzese JL; Lahoti S; Reid TR; Soetikno RM; Kirn DH; Freeman SM
    Clin Cancer Res; 2003 Feb; 9(2):555-61. PubMed ID: 12576418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer.
    El-Rayes BF; Zalupski MM; Shields AF; Ferris AM; Vaishampayan U; Heilbrun LK; Venkatramanamoorthy R; Adsay V; Philip PA
    Invest New Drugs; 2005 Dec; 23(6):583-90. PubMed ID: 16034525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) for patients with advanced pancreatic cancer: the ghost regimen.
    Reni M; Cereda S; Galli L
    Cancer Lett; 2007 Oct; 256(1):25-8. PubMed ID: 17561341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy.
    Reni M; Cereda S; Mazza E; Passoni P; Nicoletti R; Balzano G; Zerbi A; Arcidiacono PG; Staudacher C; Di Carlo V
    Am J Clin Oncol; 2008 Apr; 31(2):145-50. PubMed ID: 18391598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment trends in metastatic pancreatic cancer patients: Is it time to change?
    Reni M; Pasetto LM; Passardi A; Milella M; Mambrini A; Cereda S; Aprile G; Tronconi MC; Berardi R; Cordio S; Sartori N; Rognone A; Pederzoli P; Falconi M
    Dig Liver Dis; 2011 Mar; 43(3):225-30. PubMed ID: 21044873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas.
    Ko AH; Dito E; Schillinger B; Venook AP; Bergsland EK; Tempero MA
    J Clin Oncol; 2006 Jan; 24(3):379-85. PubMed ID: 16344320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine alone versus combination of gemcitabine and cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a retrospective analysis of multicenter study.
    Inal A; Kos FT; Algin E; Yildiz R; Dikiltas M; Unek IT; Colak D; Elkiran ET; Helvaci K; Geredeli C; Dane F; Balakan O; Kaplan MA; Durnali AG; Harputoglu H; Goksel G; Ozdemir N; Buyukberber S; Gumus M; Kucukoner M; Ozkan M; Uncu D; Benekli M; Isikdogan A
    Neoplasma; 2012; 59(3):297-301. PubMed ID: 22329849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of cisplatin combined with weekly gemcitabine in the treatment of patients with metastatic pancreatic carcinoma.
    Bang S; Jeon TJ; Kim MH; Park JY; Park SW; Chung JB; Song SY
    Pancreatology; 2006; 6(6):635-41. PubMed ID: 17159377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.